Clinical Trials Logo

Clinical Trial Summary

Spastic ataxias are a group of diseases causing symptoms such as walking difficulties and balance impairments that lead to a high risk of falls. No pharmacological treatments exist to treat these diseases. Unfortunately, little effort is made to develop non-pharmacological treatments specific to spastic ataxias despite the detrimental impact of the disease on several aspects of an individual's life and the high cost of falls for society each year. The three objectives of this project are: 1) to determine the effect of a 12-week rehabilitation program on disease severity as compared with usual care for individuals with spastic ataxias; 2) to identify which factors can help (or not) the implementation of the program in the clinical settings ("reel world"); and 3) to explore the cost-benefits of IMPACT [rehabIlitation prograM for sPAstiC aTaxias]. The team has developed the program to specifically target symptoms present in these patients and was previously pilot-tested. Based on the results obtained in this pilot project, positive effects are expected concerning the disease severity of participants. The investigators want, with this project, provide to health care professionals an option to offer better-suited services to people living with spastic ataxia worldwide.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06261424
Study type Interventional
Source Université du Québec à Chicoutimi
Contact Elise Duchesne, Ph D.
Phone 418-590-3552
Email educhesn@uqac.ca
Status Not yet recruiting
Phase N/A
Start date February 2024
Completion date March 2027